InveniAI LLC.
2614 Boston Post Road Suite #33B
Guilford CT 06437 | USA
+1-203-643-8002
innovate@inveniai.com
Deploying an AI Platform to Develop Patient Solutions at Unprecedented Scale and Speed
AlphaMeld® seamlessly integrates complex scientific, medical, chemical, and biological landscapes so that our domain experts and drug developers can quickly search for transformational treatment options at unprecedented speed and scale. With AlphaMeld®, our experts know that all the crucial data points have been considered, enabling rapid prioritization of biological targets and modalities with the most appropriate disease indication(s) while maximizing both safety and efficacy.
Know moreOur Goals are Anything but Artificial, Together we will Innovate with Intelligence.
AlphaMeld® is decoding the Gut-Brain Axis (GBA) and inflammasome pathways to drive a pipeline of therapies addressing chronic inflammatory diseases of the gut based on high unmet medical need, while maximizing localized efficacy and reducing systemic side-effects compared with the current standard of care.
Teams will work together by leveraging InveniAI's technology
April 27, 2021
Expansion of existing collaboration will leverage InveniAI
December 09, 2020
Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial
September 09, 2020
Three-year strategic collaboration to leverage InveniAI’s AI
July 29, 2020
GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global
May 11, 2021
Teams will work together by leveraging InveniAI's technology
April 27, 2021
Expansion of existing collaboration will leverage InveniAI
December 09, 2020
Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial
September 09, 2020
2614 Boston Post Road Suite #33B
Guilford CT 06437 | USA
+1-203-643-8002
innovate@inveniai.com